Order Entry
Slovenia
ContactUsLinkComponent
Human Recombinant gAdiponectin (gAcrp30), ACF
Human Recombinant gAdiponectin (gAcrp30), ACF
Catalog # STMC100-0937
CAS Number:  
undefined
Human Recombinant gAdiponectin (gAcrp30), ACF
Catalog # STMC100-0937
CAS Number:  

Specifications

  • Pk:
    100 µG
  • Protein/peptide type:
    Recombinant
  • Species:
    Human
  • Seq:
    1286
  • Protein synonyms:
    Acrp30|AdipoQ|APM-1|GBP-28|globular domain of adiponectin
  • Protein/peptide name:
    gAdiponectin (gAcrp30), ACF
  • Purity:
    ≥90%

Specifications

About this item

gAdiponectin, also known as an adipocyte component-related protein of 30 kDa, is a member of defense collagens, and its structure is similar to C1q-a member of the complement-related family of proteins (Chandran et al.). gAdiponectin is expressed by differentiated adipocytes and it is composed of three defined domains: N-terminus-containing hypervariable region, collagenous stalk containing 22 GXY repeats, followed by a C-terminus globular domain (Wang et al.). gAdiponectin has also been identified as a hematopoietic stem cell growth factor (DiMascio et al.), and is known to regulate bone marrow mesenchymal stem cell niche (Yu et al.). The globular domain of adiponectin (gAcrp30) has been shown to significantly reduce plasma-free fatty acids and glucose levels in mice (Wong et al.), and to regulate glucose and fatty acid uptake and oxidation in cardiomyocytes (Palanivel et al.). This product is animal component-free.

Caution: Product restrictions: (i) Customer shall not make products or any portion of them in any way, shape or form, including as a component of another product available for the purpose of further resale or alter or remove the Product label and the Supplier’s mark of origin without express written permission of Supplier and (ii) Customer is familiar with Supplier’s restrictions on the use of the products and shall use the products in compliance with such restrictions and the applicable Supplier Product Information sheet (collectively, the 'Product Restrictions').